| Name | Title | Contact Details |
|---|
Sobi is an international specialty healthcare company dedicated to developing treatments and extensive patient support networks for people with rare and difficult to treat diseases. These patients are often misunderstood, misdiagnosed and have limited medical options otherwise. This commitment has led to our world-class capabilities in protein biochemistry and biologics manufacturing, recognized by our leading industry partners.
At Fractyl, we are focused on improving the health of people with Type 2 diabetes. We`ve created an innovative clinical procedure based on new insights into the root cause of the disease. We are currently engaged in clinical trials designed to prove that our innovative procedure can dramatically improve glucose control and reduce the need for additional medications. Our mission is to set people free from the daily burdens of Type 2 diabetes management, empower physicians with a safe and reliable therapeutic treatment, and lower the tremendous human and financial costs of diabetic complications for patients, hospitals, and payers.
Body By Design Charleston is a locally owned and operated med spa that offers body sculpting treatments using UltraShape and VelaShape III. They also offer facial rejuvenation treatments and sell skincare products.
Bold Air Respiratory Inc is a Brick, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
BioAtla was founded in 2007 and employs deep expertise in protein engineering to develop better monoclonal antibody and other protein therapeutics. Our suite of proprietary technologies (protected by more than 70 issued patents and patent applications) has enabled us to develop dozens of novel therapeutic proteins for our partners and our own pipeline. We accelerate the process from target discovery to manufacturing and preclinical studies by creating drugs with more selective targeting, greater affinity, and more cost-efficient and predictable manufacturing. In the process we also create valuable, protectable IP that gives our partners significant competitive advantage. The culmination of our protein evolution technologies is our Conditionally Active Biologics (CAB)platform. Monoclonal antibodies or enzymes can be engineered for selective conditional activation, i.e. the protein`s functions are designed to modulate with changes in microphysical conditions (e.g., pH level, oxidation, temperature, pressure concentration, presence of certain ions, hydrophobicity and competing protein binding). Tumors and other kinds of diseased tissue give rise to unique localized conditions distinct from normal tissue. CAB designed monoclonal antibodies can be programmed to deliver an ADC payload and/or recruit the immune response to specific sites and conditions in the body.